Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In the past few years, the massively parallel sequencing capabilities of NGS have found widespread acceptance for clinical
genomics in molecular diagnostic laboratories. Due to rapid progress, the underlying technology and the associated
informatics is constantly evolving resulting in considerable process improvements in relatively short durations. Although
desirable, these constant upgrades pose a challenge for clinical sequencing assays being used for clinical purposes due to the
need of through validation before implementation. Here, in the context of a CAP and CLIA accredited molecular diagnostic
laboratory the advantages and challenges posed by the constant upgrades for routine NGS testing of solid tumors and
hematological malignancies will be presented. The progress in the wet bench and informatics portions of major NGS platforms
will be highlighted.
Rajesh Singh has a PhD in Biochemistry from The University of Mysore, India and Postdoctoral research experience from University of Texas, MD Anderson Cancer
Center. He has extensive experience in cancer biology focusing on the deregulated oncogenic and tumor suppressor pathways in the origin and maintenance of
solid tumors and hematological malignancies. He is an Assistant Professor and Director Clinical NGS Development in the molecular diagnostics laboratory at MD
Anderson, where he supervises the design and validation of the NGS assays for routine mutational screening of tumors. He has published more than 40 papers
and 3 review articles in reputed journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals